CDK4 and cancer: These results suggest a potential role for PRGPRP in modulating Cdk4/Cdk1 co-expression in parallel with cancer cell killing and point to the possibility of the Cdk1/Cdk4 ratio as being a potential companion theranostic biomarker for PRGPRP anticancer activity.